137 results
Page 5 of 7
8-K
EX-1.1
jzgm9au9y02qeb5faf
21 Feb 20
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
4:46pm
424B5
90w229urx8ro4ieam
21 Feb 20
Prospectus supplement for primary offering
4:26pm
424B5
riey5
20 Feb 20
Prospectus supplement for primary offering
5:28pm
8-K
EX-99.1
j1c5 bfx00ylf
20 Feb 20
Agile Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
4:27pm
8-K
EX-4.1
dhkbrlo3avozm caj7
12 Feb 20
Entry into a Material Definitive Agreement
8:00am
8-K
EX-10.1
h6vp29m
12 Feb 20
Entry into a Material Definitive Agreement
8:00am
8-K
EX-4.2
9dl 8qphy
12 Feb 20
Entry into a Material Definitive Agreement
8:00am
8-K
EX-99.1
px93jqk
14 Nov 19
Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period
4:38pm
8-K
EX-1.1
p5dm3fx2k3 42o6rbmb8
8 Nov 19
Entry into a Material Definitive Agreement
4:38pm
424B5
rpppkwwce oxo50b9b9
8 Nov 19
Prospectus supplement for primary offering
4:34pm
8-K
EX-99.1
6looq 8a3sfmi
31 Oct 19
Committee Votes 14 to 1, with 1 Abstention, in Favor of Approval
4:30pm
8-K
EX-1.1
z5owdr
2 Aug 19
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
4:50pm
424B5
h4x5je
2 Aug 19
Prospectus supplement for primary offering
4:40pm
424B5
bjozkvmfnjn hc
1 Aug 19
Prospectus supplement for primary offering
4:21pm